Both companies’ stocks rose in the wake of the news.

Hims & Hers Health (HIMS) rose ~57% this week, marking its best-ever weekly advance after the telehealth firm ended a months-long dispute with Novo Nordisk (NVO) and agreed to sell the pharma giant’s ...

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...

The crucial question is whether the terms of the partnership allow for profitable expansion or merely position HIMS as a ...

March 9 (Reuters) - Hims & Hers' shares were up over 50% in premarket trading on Monday following reports Novo Nordisk plans ...

On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth growth.

Hims & Hers stock traded more than 40% higher after the deal was announced.

The agreement brings an end to the legal dispute between the two companies. Hims & Hers shares jumped.

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will ...

Hims & Hers Health Inc. surged after Novo Nordisk A/S was said to have ended its public feud with the company with an agreement to sell its weight-loss drugs on the Hims platform.

Hims & Hers Health, Inc.'s revenue is projected to reach $2.7B in 2026 & $3.2B in 2027, implying less than 2x forward sales. Read more on HIMS stock here.